American College of Cardiology / American Heart Association Guidelines: New Heart Failure Guidelines Stress Early Diagnosis and Treatment
Posted on: Tuesday, 16 August 2005, 12:01 CDT
DALLAS, Aug. 16 /PRNewswire/ -- Early diagnosis and new treatments can help battle heart failure -- a growing national problem that causes 1 million hospital admissions each year, according to new guidelines released today by the American College of Cardiology (ACC) and the American Heart Association (AHA).
The document is available today on the Web sites of the ACC (http://www.acc.org/ ) and the AHA (http://www.americanheart.org/ ) and will be published in the Sept. 20, 2005, issues of the Journal of the American College of Cardiology, and Circulation: Journal of the American Heart Association along with the ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure and the ACC/AHA Key Data Elements and Definitions for Measuring Clinical Measurements and Outcomes of Patients with Chronic Heart Failure.
Noting that new treatment approaches may also improve the quality of life for patients, the authors classified heart failure on a scale from risk factors to end-stage disease:
-- Stages A and B are when patients lack early signs or symptoms of heart failure, but are at risk because of risk factors or heart abnormalities, which could include a change in the shape or structure of the heart. -- Stage C denotes patients with current or past heart failure symptoms such as shortness of breath. -- Stage D designates patients with refractory heart failure who might be eligible for specialized advanced treatment -- including cardiac transplantation -- or compassionate end-of-life care such as hospice.
Nearly any form of heart disease may ultimately lead to heart failure. The guidelines stress that early recognition and proper treatment of high blood pressure, diabetes, coronary artery disease and other cardiovascular risk factors can help patients delay or avoid heart failure.
The key to prevention is to get the risk factors under control. For instance, studies have shown controlling hypertension can reduce the incidence of heart failure by 50 percent.
"More treatments have made our decision-making far more complex since the last ACC/AHA heart failure guidelines only four years ago," said Sharon Ann Hunt, M.D., F.A.C.C., professor of cardiovascular medicine at Stanford University Medical Center and chair of the writing group.
From 1990-99, the number of people hospitalized with a primary diagnosis of heart failure increased from 810,000 to more than 1 million. This was due to the population aging and to more people surviving heart attacks. Heart failure mostly affects the elderly, and more Medicare dollars are spent for heart failure diagnosis and treatment than for any other disease.
About 5 million U.S. residents are living with heart failure, and more than 550,000 people are diagnosed with the condition each year. In 2005 the disease will cost an estimated $27.9 billion in direct and indirect health care expenses, the authors write.
Some people may not realize one of the main symptoms of heart failure is becoming easily exhausted.
"We know there are many people walking around who think they are just out of shape or that they are just getting older, or that their ankles are swelling because it's hot," said co-author Mariell Jessup, M.D., F.A.C.C., medical director of the heart failure and cardiac transplantation program and professor of medicine at the University of Pennsylvania Medical Center in Philadelphia. "They don't appreciate that this may be due to heart failure."
The guidelines also change the name of the condition from congestive heart failure (CHF) to heart failure (HF) to reflect the broad spectrum of the disease. Congestion occurs when the heart cannot efficiently pump or eject blood from its chambers. This causes fluid build-up in the lungs and heart, resulting in stiff, fluid-filled lungs and shortness of breath. The panel dropped the word 'congestive' because people can have few or no symptoms of congestion, and still have a severely abnormal heart with symptoms of fatigue and exercise intolerance caused by poor cardiac output, Jessup said.
In recent years, doctors have recognized that many people with normal ejection fraction have heart failure. This often occurs because the heart pumps properly, but fails to fill adequately with blood, a condition called diastolic heart failure. These patients rarely have been included in clinical trials of new drugs and devices in the past, but they are the subjects of several new, ongoing trials. These trials should help settle the issue of whether their treatment should be the same as that for patients with reduced ejection fraction.
"The second major point is that heart failure does not go away," Jessup said. "There are drugs that need to be used and medical care that needs to be done on a regular basis."
The committee also recommended left ventricular assist devices (LVADs) be considered as permanent or "destination" therapy in selected patients.
LVADs are implanted mechanical devices that help pump blood through the heart and can be used as a reasonable permanent therapy in some end-stage heart failure patients who are not candidates for transplants, don't respond to standard treatment and have a one-year survival outlook of less than 50 percent. The devices, which recently received U.S. Food and Drug Administration approval as permanent or "destination" therapy, were first used as a temporary measure to keep patients alive while awaiting a heart transplant. "It's going to be a whole new era in treating heart failure," Jessup said. "Eventually, we'll have portable artificial pumps that can take over the action of the heart."
Other recommendations: -- Expand the number of patients eligible for implantable cardioverter-defibrillators (ICDs), devices implanted under the skin that save lives by shocking chaotic heart rhythms back into a healthy pattern. *** -- Provide information on end-of-life issues. Although treatment advances can extend lives, heart failure is often fatal. The guidelines recommend that cardiologists broach the subject of hospice care -- support and comfort for dying patients and their families.
"There is a failure to recognize that end-stage heart failure patients frequently come in and out of the hospital over and over again and suffer a lot with really no impact on their ultimate survival," Jessup said. "I think using hospice is a way of improving the remaining days that these patients have. Hospice can be a very positive experience for patients and their families."
She acknowledged that this represents a new role for many cardiologists.
"Cardiologists aren't used to talking about hospice. They are more used to doing interventions. So it is a big shift," she said.
The guidelines also suggest that a new perspective on treating end-stage heart failure could result in a smoother, less stressful transition for patients and their families.
Co-authors and members of the Heart Failure Guidelines Writing Committee: William T. Abraham, M.D., F.A.C.C.; Marshall H. Chin, M.D., M.P.H.; Arthur M. Feldman, M.D., Ph.D. F.A.C.C.; Gary S. Francis, M.D., F.A.C.C.; Theodore G. Ganiats, M.D.; Marvin A. Konstam, M.D., F.A.C.C.; Donna M. Mancini, M.D.; Keith Michl, M.D.; John A. Oates, M.D.; Peter S. Rahko, M.D., F.A.C.C.; Marc A. Silver, M.D., F.A.C.C.; Lynne Warner Stevenson, M.D., F.A.C.C; and Clyde W. Yancy, M.D., F.A.C.C.
Other organizations that participated in the development of the guidelines were the American Academy of Family Physicians, the American College of Physicians, the American College of Chest Physicians, the Heart Failure Society of America and the International Society for Heart and Lung Transplantation.
*** Editor's note: The final version of these guidelines have further expanded the number of patients who should be considered for ICDs, by adding the recommendation that patients with ischemic cardiomyopathy, functional class 1 with low ejection fraction be considered for ICD placement (MADIT II trial).
Editor's note: The American Heart Association has many heart failure tools and resources to assist patients, caregivers and healthcare providers available through http://www.americanheart.org/heartfailure .
NR05 - 1096 (Circ/Hunt) Heart Failure Facts What is heart failure (HF)? Heart failure is a chronic, progressive condition in which the heart is unable to pump enough blood to the body's other organs. It is not a heart attack nor does it mean the heart has stopped working. Heart failure is a growing epidemic in the United States, due in part to the aging population. How many people are affected by heart failure? An estimated 5 million U.S. residents are living with heart failure, and more than 550,000 people are diagnosed with the condition each year. What are the four stages of heart failure? The American Heart Association and the American College of Cardiology guidelines view heart failure as a continuum from risk factors to end- stage disease. Noting that new treatment approaches may also improve the quality of life for patients, the authors classified heart failure on a scale from risk factors to end-stage disease: -- Stages A and B are when patients lack early signs or symptoms of heart failure, but are at risk because of risk factors or heart abnormalities, which could include a change in the shape or structure of the heart. -- Stage C denotes patients with current or past heart failure symptoms such as shortness of breath. -- Stage D designates patients with refractory heart failure who might be eligible for specialized advanced treatment -- including cardiac transplantation -- or compassionate end-of-life care such as hospice. Is 'heart failure' now the preferred term rather than 'congestive heart failure'? Yes. Congestion occurs when the heart cannot "pump" or eject blood from its chambers efficiently. This causes fluid to build up in the lungs and heart, resulting in shortness of breath. Not all patients have fluid overload when they are diagnosed with heart failure, so the writing group favors the broader term "heart failure." Furthermore, in recent years there has been a growing recognition that people can have few or no symptoms of congestion and still have a severely abnormal heart. There is also an increasing awareness of the number of people with heart failure and a normal ejection fraction. In that condition, the heart's ejection fraction, or pumping ability, may be normal but stiffness in the heart muscle keeps the heart from properly filling with blood. Patients with diastolic heart failure tend to experience extreme fatigue and reduced exercise capacity, rather than the shortness of breath that marks congestive heart failure. In the past, patients with diastolic heart failure were rarely included in clinical trials of new drugs and devices. That's changing now, and several ongoing clinical trials should provide insight into diagnosing and treating diastolic heart failure. What are some of the changes from previous guidelines? -- One change involves left-ventricular assist devices (LVADs), which are implanted machines that help the heart pump. They were first used as temporary therapy for patients awaiting heart transplants, but are now considered reasonable permanent therapy in some situations. -- The new guidelines also expand the number of patients eligible for implantable cardioverter-defibrillators (ICDs). These devices save lives by shocking chaotic heart rhythms back into a healthy pattern. -- Although treatment advances can extend lives, heart failure is often fatal. The guidelines recommend that cardiologists introduce the subject of hospice care -- support and comfort for dying patients and their families -- for patients with end-stage HF. American Heart Association's Programs and Tools on Heart Failure
About 5 million people suffer from heart failure and the incidence has not declined in two decades. The American Heart Association provides valuable resources in various ways to those who live with heart failure each day. The science and research funded, published in American Heart Association journals and presented at American Heart Association meetings helps educate professionals and provide incentive to researchers who continue to investigate heart failure. Also, the American Heart Association transfers this research into applicable tools and programs that benefit and educate consumers who have been diagnosed with heart failure.
For Patients: Heart Failure Web site
Launched in 1999, this content area of the American Heart Association's Web site offers tools and support for loved ones and people diagnosed with heart failure. An interactive message board, e-cards and a monthly newsletter, among other tools, are available at http://www.americanheart.org/heartfailure .
Heart Profiler
Heart Profilers are free, interactive tools specific to many heart conditions, including heart failure. It provides patients, loved ones and caregivers with standard treatment options and descriptions of possible side effects. The Heart Profilers tools also generate confidential, personalized reports that enable patients to have a more meaningful dialogue with their healthcare provider. There is also a professional component of the tool that provides physicians and other healthcare professionals access to abstracts of published studies based on their patient's overall condition among other tools. Log on to the Heart Profilers at http://www.americanheart.org/heartprofilers .
Patient education resources
Free brochures and education sheets on heart failure can be printed or ordered by visiting http://www.americanheart.org/ or calling 1-800-AHA-USA1.
For Professionals: Get With The Guidelines -- Heart Failure
Get With The Guidelines(SM) is a quality improvement initiative that provides hospital staff tools that follow proven evidence-based guidelines and procedures for heart failure patients in their care to prevent future hospitalizations.
The program includes quality-improvement measures such as care maps, discharge protocols, standing orders and measurement tools. This quick and efficient use of guideline tools enables hospitals to improve the quality of care provided to heart failure patients, save lives and ultimately, reduce healthcare costs by lowering the recurrence of heart attacks. To find out how this program can be implemented in your hospital, visit http://www.americanheart.org/getwiththeguidelines .
Professional Satellite Symposium
American Heart Association Heart Failure Satellite Broadcasts is a new continuing education broadcast series with world-class faculty focusing on evidence-based treatment options for the heart failure patient from diagnosis to outcomes. Upcoming programs include Diagnosis of Heart Failure (09/07/05), In-Hospital Treatment Strategies for Heart Failure (09/14/05) and Advances in the Management of Heart Failure Post-Discharge (09/21/05). All 3 programs are 12-1 pm EDT. To register and for more information including rebroadcast dates and times, visit http://www.heartcmeprograms.org/ .
Patient education resources
Free brochures and education sheets on heart failure can be printed or ordered by visiting http://www.americanheart.org/ or calling 1-800-AHA-USA1.
American College of Cardiology; American Heart Association
CONTACT: Sharon Ann Hunt, M.D., F.A.C.C. of Stanford University MedicalCenter, +1-650-498-6605, or shunt@cvmed.stanford.edu ; or Mariell Jessup,M.D., F.A.C.C. of University of Pennsylvania Medical Center, +1-215-615-0808,or jessupm@uphs.upenn.edu ; or Karen Astle of American Heart Association,+1-214-706-1392; or Anne Dees of American College of Cardiology,+1-301-581-3406. Please do not publish contact information.
Web site: http://www.acc.org/http://www.americanheart.org/http://www.americanheart.org/heartfailurehttp://www.americanheart.org/heartprofilershttp://www.americanheart.org/getwiththeguidelineshttp://www.heartcmeprograms.org/
Source: PRNewswire
Related Articles
- American Heart Association Late-Breaking Clinical Trial Report: Tailoring Drug Dose to Heart Failure Patients' Response More Effective
- American Heart Association Late Breaking Clinical Trial Report: High Dose of Angiotensin Receptor Blockers Effective in Heart Failure Patients
- Many Heart Failure Patients Do Not Get Proper Drug Treatments
- Hospital Care for Heart Attack, Heart Failure Patients Varies Across Nation
- Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
- Clinical Data Show CVRx(R) Rheos(R) Therapy Improved Heart Structure and Function in Early-Stage Heart Failure Patients
- Merck's Investigational Rolofylline Associated With Improved Dyspnea and Preserved Renal Function in Acute Heart Failure Patients in a Phase III Pilot Study
- Heart Failure Patients Aided By Nurse Care
- Research Suggests That Cardiac Marker NT-proBNP is a Better Predictor for Mortality Than BNP in Heart Failure Patients With Reduced Kidney Function
- Role of Cholesterol Lowering Drugs in Heart Failure Patients Evaluated in Yale Medical Center's Heart Study
User Comments (0)

RSS Feeds